Search Results - "SOO PEANG KHOR"

The pharmacokinetics and pharmacodynamics of levodopa in the treatment of Parkinson's disease by Khor, Soo-Peang, Hsu, Ann

“…Levodopa, a prodrug of dopamine, remains to be one of the main drugs in the treatment of Parkinson's disease. All current levodopa products are formulated with…”
Get more information

Inhibition of Cytosolic Phospholipase A2α: Hit to Lead Optimization by McKew, John C, Foley, Megan A, Thakker, Paresh, Behnke, Mark L, Lovering, Frank E, Sum, Fuk-Wah, Tam, Steve, Wu, Kun, Shen, Marina W. H, Zhang, Wen, Gonzalez, Mario, Liu, Shanghao, Mahadevan, Anu, Sard, Howard, Khor, Soo Peang, Clark, James D

“…Compound 1 was previously reported to be a potent inhibitor of cPLA2α in both artificial monomeric substrate and cell-based assays. However, 1 was inactive in…”
Get full text

Pharmacokinetics, pharmacodynamics, allometry, and dose selection of rPSGL-Ig for phase I trial by Khor, S P, McCarthy, K, DuPont, M, Murray, K, Timony, G

“…rPSGL-Ig is a recombinant, soluble, and chimeric form of P-selectin glycoprotein ligand-1, which is developed as an antagonist to P-selectin. Allometric and…”
Get more information

Phase I and Pharmacologic Study of Oral Fluorouracil on a Chronic Daily Schedule in Combination With the Dihydropyrimidine Dehydrogenase Inactivator Eniluracil by BAKER, S. D, DIASIO, R. B, ROWINSKY, E. K, O'REILLY, S, LUCAS, V. S, SOO PEANG KHOR, SARTORIUS, S. E, DONEHOWER, R. C, GROCHOW, L. B, SPECTOR, T, HOHNEKER, J. A

“…To determine the maximum-tolerated dose (MTD), toxicities, and pharmacokinetics of oral fluorouracil (5-FU) administered twice daily in combination with oral…”
Get full text

Gel electrophoresis–autoradiographic image analysis of radiolabeled protein drug concentration in serum for pharmacokinetic studies by Song, Di, Ma, Shang, Khor, Soo-Peang

“…Introduction: The purpose of this study was to evaluate the feasibility of using gel electrophoresis combined with autoradiographic image analysis for…”
Get full text

An oxygenation agent and radiation sensitizer, dodecafluoropentane, for the treatment of glioblastoma multiforme by Lickliter, Jason D., Wilson, David Brown, Hendrickson, Howard, Raghunand, Natarajan, Khor, Soo-Peang, Longacre, Olivia, Unger, Evan C.

“…Abstract only…”
Get full text

A modified equilibrium dialysis technique for measuring plasma protein binding : Experimental evaluation with diazepam and nortriptyline by CHOW, H.-H, SOO PEANG KHOR, LEE, H.-C, MAYERSOHN, M

Get full text

Discovery of ecopladib, an indole inhibitor of cytosolic phospholipase A2α by LEE, Katherine L, FOLEY, Megan A, KHOR, Soopeang, XIN XU, GOODWIN, Debra G, RAMARAO, Manjunath K, NICKERSON-NUTTER, Cheryl, DONAHUE, Frances, SHERRY KU, M, DARK, James D, MCKEW, John C, CHEN, Lihren, BEHNKE, Mark L, LOVERING, Frank E, KIRINCICH, Steven J, WEIHENG WANG, SHIM, Jaechul, TAM, Steve, SHEN, Marina W. H

Get full text

Abstract 3202: Imetelstat inhibits telomerase activities in xenograft tumors and bone marrow cells and inhibits tumor growth in xenograft models at plasma exposures equivalent to current clinical exposures in Phase I trials by Go, Ning F., Villarreal, Lyssa, Pattamata, Preeti, Nazzal, Denise, Lin, Tong, Khor, Soo-Peang, Delavan-Boorsma, Karen, Tressler, Robert

“…Abstract Telomerase activation is a hallmark of cancer and is critical for dysregulated cell proliferation and cell immortality. Increased telomerase…”
Get full text

Area-based estimation of the initial volume of distribution and elimination rate constant following intravenous bolus injection by Khor, S P, Johnson, S L, Mayersohn, M

“…We evaluate here an area term, the area under the rate of change of concentration-time curve (AURC), which allows the determination of the initial or central…”
Get more information

Results of a Phase I Study of GRN163L, a Direct Inhibitor of Telomerase, in Patients with Relapsed and Refractory Multiple Myeloma (MM) by Chanan-Khan, Asher Alban, Munshi, Nikhil C., Hussein, Mohamad A., Elias, Laurence, Benedetti, Fabio, Smith, Jennifer, Khor, Soo-Peang, Huff, Carol A.

“…Telomerase over-expression is the predominant mechanism by which cancer cells maintain adequate telomere length to achieve immortalization. Telomere length is…”
Get full text

Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer by Schilsky, R L, Hohneker, J, Ratain, M J, Janisch, L, Smetzer, L, Lucas, V S, Khor, S P, Diasio, R, Von Hoff, D D, Burris, 3rd, H A

“…To determine the highest dose of fluorouracil (5-FU) that could be safely administered with Eniluracil (776C85; Glaxo Wellcome Inc, Research Triangle Park,…”
Get more information

Inhibition of cytosolic phospholipase A2alpha: hit to lead optimization by McKew, John C, Foley, Megan A, Thakker, Paresh, Behnke, Mark L, Lovering, Frank E, Sum, Fuk-Wah, Tam, Steve, Wu, Kun, Shen, Marina W H, Zhang, Wen, Gonzalez, Mario, Liu, Shanghao, Mahadevan, Anu, Sard, Howard, Khor, Soo Peang, Clark, James D

“…Compound 1 was previously reported to be a potent inhibitor of cPLA(2)alpha in both artificial monomeric substrate and cell-based assays. However, 1 was…”
Get full text

Inhibition of Cytosolic Phospholipase A 2 α: Hit to Lead Optimization by McKew, John C., Foley, Megan A., Thakker, Paresh, Behnke, Mark L., Lovering, Frank E., Sum, Fuk-Wah, Tam, Steve, Wu, Kun, Shen, Marina W. H., Zhang, Wen, Gonzalez, Mario, Liu, Shanghao, Mahadevan, Anu, Sard, Howard, Khor, Soo Peang, Clark, James D.

Get full text

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics: allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans by Khor, S. P., Amyx, H., Davis, Stephen T., Nelson, Donald, Baccanari, David P., Spector, Thomas

Get full text

Oral delivery of recombinant human interleukin-11 decreases clinical signs and histologic lesions in animal models of inflammatory bowel disease by Carl Keith, James, Albert, Leo, Marchese, Erik, Tseng, Leo C-M, McCarthy, Kyle, Peterson, Ron L., Domer, Andrew J., Khor, Soo Peang, Schaub, Robert G.

Get full text

In vivo absorption properties of orally administered recombinant human interleukin-11 by TSENG, C.-M. L, ALBERT, L, PETERSON, R. L, BOUCHARD, P, DORNER, A. J, KEITH, J. JR, KHOR, S.-P

Get full text

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. I. Theoretical considerations by Khor, S P, Mayersohn, M

“…Physiological pharmacokinetic models require the determination of tissue to blood distribution coefficients. A theoretical model has been developed and the…”
Get more information

Dihydropyrimidine dehydrogenase inactivation and 5-fluorouracil pharmacokinetics : allometric scaling of animal data, pharmacokinetics and toxicodynamics of 5-fluorouracil in humans by SOO PEANG KHOR, AMYX, H, DAVIS, S. T, NELSON, D, BACCANARI, D. P, SPECTOR, T

“…The pharmacokinetics of 5-fluorouracil (5-FU) in different animal species treated with the dihydropyrimidine dehydrogenase (DPD) inactivator, 5-ethynyluracil…”
Get full text

Potential error in the measurement of tissue to blood distribution coefficients in physiological pharmacokinetic modeling. Residual tissue blood. II. Distribution of phencyclidine in the rat by Khor, S P, Bozigian, H, Mayersohn, M

“…A model for predicting the magnitude of error (% Err) in measuring tissue concentrations of a compound that have not been corrected for residual blood in the…”
Get more information